The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

Astellas has struck a deal with fellow Japanese pharma company Elpiscience to develop up to four cancer immunotherapies that work by revving up the activity of macrophages against tumour cells.

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

Transitioning from my role as a pharmacist to becoming a project manager in healthcare technology was not just a professional milestone, but a deeply transformative journey. As a pharmacist, I saw ...

AstraZeneca's EGFR inhibitor Tagrisso has become the first drug in the class to be approved in the EU as a treatment for a specific form of locally advanced, unresectable non-small cell lung ...

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

In 2023, the life sciences industry was rocked by generative artificial intelligence (GenAI), which showed the potential to revolutionise everything from genetic understanding and drug research to ...

AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and Wales. Final draft ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

As the drug development landscape becomes more complex, pharmaceutical and biotech companies understand their business strategies have to evolve. This need is putting a spotlight on how clinical ...